Mitragynine: Active Alkaloid in Kratom — What Research Shows

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making health decisions based on this content.

By KratomCBDDirect.com Editorial Team | Last verified: August 2026

What Mitragynine Is — Chemical Classification and Sources

Mitragynine is an indole-based alkaloid—a naturally occurring chemical compound—found primarily in the leaves of Mitragyna speciosa, the plant commonly known as kratom. It is native to Southeast Asia, particularly Thailand and Malaysia, and has been used in traditional medicine and labor practices for at least 100 years.

Mitragynine is the most abundant active alkaloid in kratom leaves. Concentration varies by geographic origin:

• Thai kratom: Up to 66% of total alkaloid content
• Malaysian kratom: Approximately 12% of total alkaloid content
• Typical whole-leaf kratom: 0.5–1.5% total alkaloid concentration by weight

Kratom leaves are typically consumed as dried powder mixed into capsules, brewed as tea, or incorporated into concentrated extracts. The alkaloid profile—including not only mitragynine but also 7-hydroxymitragynine (7-OH), speciociliatine, and dozens of other alkaloids—contributes to kratom's overall effects.

How Mitragynine Works — Biological Mechanisms

Mitragynine functions as a partial agonist of the μ-opioid receptor (mu-opioid receptor), a cellular binding site involved in pain signaling, mood regulation, and reward processing. This mechanism is similar to how classical opioids like morphine work, but mitragynine's partial agonism means it produces weaker and potentially safer effects than full opioid agonists.

Dose-dependent effects: Kratom users report distinctly different effects based on quantity consumed:

• Low doses (1–5 grams): Mild stimulation, increased alertness, mild euphoria
• High doses (5–15+ grams): Sedation, analgesia (pain relief), and relaxation

This biphasic dose response is characteristic of opioid-like activity. The exact mechanisms underlying the stimulant effects at low doses are not fully understood but may involve interactions with other alkaloid-receptor systems.

Beyond opioid receptors, mitragynine and related alkaloids have shown in laboratory and animal studies the potential to modulate inflammatory and pain pathways, though human clinical evidence is limited.

What the Research Shows — Evidence on Mitragynine Efficacy

Pain Management — Preliminary Evidence

Traditional use for pain mitigation in Southeast Asia spans at least one century, particularly among laborers using kratom to ease physical discomfort and sustain endurance.

Laboratory evidence: A 2016 rat study found that kratom alkaloid extracts produced antinociceptive (pain-blocking) effects comparable to oxycodone in standard pain tests (hotplate and tail-flick models). These effects were reversed by naloxone, an opioid-receptor antagonist, supporting the opioid-like mechanism.

User reports: Kratom is commonly self-administered in the United States for chronic pain. A 2019 literature review suggested potential for kratom as substitution therapy in chronic pain management, though the authors emphasized the lack of controlled clinical trials.

Evidence grade: Preliminary. Animal model data is promising; human clinical trials are absent.

Opioid Withdrawal — Promising but Understudied

Historical use of kratom for opioid addiction and withdrawal dates to at least the 19th century in Southeast Asia. Modern surveys suggest this remains a primary motivation for kratom use:

• In one survey of approximately 8,000 kratom users, nearly 50% reported reduced or discontinued opioid use after taking kratom

Animal model evidence: Zebra fish and rodent models show that mitragynine can suppress withdrawal symptoms from other opioids (e.g., after chronic morphine administration).

Clinical trial data: None exist as of 2024. The FDA noted in 2018 that no clinical trials had studied kratom's safety or efficacy for opioid withdrawal. This remains a major research gap.

Evidence grade: Anecdotal + preliminary animal evidence. Human clinical data required before therapeutic claims are justified.

Forms and Bioavailability of Mitragynine

Solubility challenges: Mitragynine has very low solubility in neutral to alkaline water (0.0187 mg/mL at pH 9), but higher solubility in acidic conditions (3.5 mg/mL at pH 4). This has practical implications:

• Whole-leaf tea brewed in water: Lower mitragynine extraction; variable absorption
• Acidified beverages: Better extraction but shorter shelf life; mitragynine becomes unstable over time
• Capsules with powder: Consistent dosing; absorption depends on stomach pH and intestinal transit
• Concentrated extracts: Vendors claim improved bioavailability, but formulation quality and mitragynine stability vary widely; no standardized product testing exists

No published studies directly compare bioavailability across these forms in humans. Oral consumption is standard; intravenous use is not advised and not studied.

Who Should Consider Mitragynine — and Who Should Avoid It

Potential Users

People interested in mitragynine/kratom typically fall into two categories:

• Pain management seekers: Individuals with chronic or acute pain seeking non-pharmaceutical options, though clinical validation is lacking
• Opioid withdrawal support: Individuals attempting to reduce or discontinue opioid medications, often under self-direction rather than medical supervision

Safety and Side Effects of Mitragynine

Dependence and Withdrawal

Dependence risk: Regular, long-term use of mitragynine can lead to physical dependence. In animal studies, withdrawal symptoms mirrored opioid withdrawal: anxiety, teeth chattering, and piloerection (body-hair standing on end).

Withdrawal timeline: In one small human study, withdrawal symptoms lasted less than three days for most subjects, though severity and duration vary individually.

Withdrawal symptoms reported by users include: Irritability, anxiety, muscle aches, insomnia, sweating, and cravings.

Toxicity and Overdose

Fatal overdoses involving kratom are rare but documented, typically in combination with other opioids or CNS depressants. There is no established lethal dose for mitragynine alone in humans.